LumiraDx Ltd - Company Profile
Powered by 
All the data and insights you need on LumiraDx Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date LumiraDx Ltd Strategy Report
- Understand LumiraDx Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
LumiraDx Ltd (LumiraDx) is a company that provides point-of-care (PoC) diagnostic tests and solutions. The company is focused on transforming community-based healthcare by giving essential diagnostic information to healthcare practitioners at the time of need, enabling better informed medical decisions to enhance health outcomes while decreasing costs. Its product portfolio includes severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) antigen test, SARS-CoV-2 antibody test, INR test, and D-Dimmer test. It offers solutions such as to engage, a patient program; INRstar, an anticoagulation software; and DataWell, a data-sharing solution. The company’s products are built on its proprietary, LumiraDx platform. LumiraDx is also evaluating pipeline products at various stages of development for screening infectious diseases, diabetes, and cardiovascular diseases. The company sells its products through a direct sales force and a network of distributors in the US, Europe, Japan, South Africa, Colombia, and Brazil. LumiraDx is headquartered in London, the UK.
Headquarters
United Kingdom
Address
Windward 3, Regatta Office, Po Box 1350, Grand Cayman, Cayman Islands, KY1-1108
Website
www.lumiradx.com
Telephone
44 1786 430411
No of Employees
1,210
Industry
Medical Equipment
Ticker Symbol & Exchange
LMDXF (OTC)
Revenue (2021)
$254.5M
-39.6%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
-343.7%
(2021 vs 2020)
Market Cap*
$2.5M
Net Profit Margin (2021)
XYZ
-634.7%
(2021 vs 2020)
* As of and is in US$
LumiraDx Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| SARS-CoV-2 Antigen Test |
| SARS-CoV-2 Antibody Test |
| INR Test |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company entered into an agreement to sell its innovative Point of Care technology to Roche. |
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with AstraZeneca & Everton in the Community to set up England’s first community-based heart and lung screening hub. |
| 2023 | Contracts/Agreements | In July, the company entered into an agreement with Axon Lab AG for the commercialization of its LumiraDx Platform and diagnostic tests to include exclusive distribution rights in Switzerland. |
Competitor Comparison
| Key Parameters | LumiraDx Ltd | Abbott Laboratories | Danaher Corp | Siemens Healthineers AG | Becton Dickinson and Co |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | United States of America | Germany | United States of America |
| City | Grand Cayman | Abbott Park | Washington | Forchheim | Franklin Lakes |
| State/Province | Cayman Islands | Illinois | WashingtonD.C. | - | New Jersey |
| No. of Employees | 1,210 | 114,000 | 61,000 | 71,400 | 73,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ron Zwanziger | Chairman; Chief Executive Officer | Executive Board | 2014 | 69 |
| David Scott, Ph.D. | Director; Chief Technology Officer | Executive Board | 2016 | 67 |
| Jerry McAleer, Ph.D. | Director; Chief Scientist | Executive Board | 2014 | 68 |
| Dorian LeBlanc | Vice President - Global Operations; Chief Financial Officer | Senior Management | 2016 | 48 |
| Pooja Pathak | Chief Product Officer | Senior Management | 2020 | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer